Alphabet’s ambitious drug discovery venture, <a href="https://news.quantosei.com/2025/07/06/google-deepmind-is-ready-to-start-human-trials-of-ai-designed-drugs-company-exec-says-were-getting-ve/” title=”Breaking: Google DeepMind AI Drugs Ready for Human Trials”>isomorphic Labs, is reportedly on the cusp of a monumental step: testing its AI-generated medicines in human clinical trials. Spun out from Google DeepMind in 2021, Isomorphic Labs is leveraging cutting-edge artificial intelligence, born from DeepMind’s revolutionary protein-folding technology, AlphaFold, with the audacious aim of transforming how diseases are treated.
Colin Murdoch, president of Isomorphic Labs and chief business officer at Google DeepMind, confirmed that preparations are well underway. Speaking from Paris, he noted that researchers in their London office are actively collaborating with AI systems right now to design potential drug candidates, including treatments for cancer. This signals a significant shift from theoretical AI models to practical application at the forefront of medical research.
From Protein Structure to Drug Design Engine
The foundation of Isomorphic Labs lies in one of Google DeepMind’s most celebrated achievements: AlphaFold. This groundbreaking AI system initially demonstrated an unprecedented ability to accurately predict the 3D structures of individual proteins. Understanding protein shapes is fundamental to biology and drug design, as proteins are often the targets that medicines interact with.
AlphaFold’s capabilities didn’t stop there. The technology rapidly evolved, progressing from predicting single protein structures to modeling how proteins interact with other critical molecules, including DNA and existing pharmaceutical compounds. This leap was transformative, dramatically enhancing AlphaFold’s utility for drug discovery by allowing researchers to identify potential drug targets and design molecules that could precisely bind to them.
Murdoch highlighted that this progression in AlphaFold’s ability to understand molecular interactions was the direct inspiration for establishing Isomorphic Labs. It proved that foundational breakthroughs in AI could directly address and potentially unlock core challenges within the complex process of discovering new medicines.
Gearing Up for Human Clinical Trials
After years of intensive development and refinement of its AI models, Isomorphic Labs now sees human clinical trials firmly on the horizon. Murdoch stated that getting these AI-designed drug candidates into human testing is the “next big milestone” for the company.
To facilitate this critical transition, Isomorphic Labs is actively expanding its team. They are currently staffing up, bringing in the necessary expertise and resources to manage the rigorous demands of clinical trials. This recruitment drive indicates they are nearing readiness to begin the complex process of evaluating the safety and efficacy of their AI-generated compounds in people.
Building a World-Class Drug Design Capability
Isomorphic Labs’ strategy isn’t just about applying AI; it’s about creating a fundamentally new approach to drug development. The company is focused on building what Murdoch described as a “world-class drug design engine.” This engine combines the sophisticated analytical power of machine learning researchers with the deep, practical experience of pharmaceutical industry veterans.
The primary objectives of this integrated approach are ambitious: to design new medicines significantly faster, reduce the immense costs traditionally associated with drug development, and, crucially, dramatically improve the likelihood of success in clinical trials.
Currently, the journey to bring a single drug to market is notoriously challenging and expensive. Pharmaceutical companies can spend millions of dollars over many years, and even once clinical trials begin, the probability of a drug ultimately receiving approval is often only around 10%. Isomorphic Labs believes its AI-driven platform can radically alter these odds.
Murdoch expressed the hope that their technology could enable researchers to reach a point where they have “100% conviction” in the potential success of the drugs they are developing before they enter human trials. This level of predictive accuracy could revolutionize the efficiency and cost-effectiveness of the entire process. The long-term vision is even more transformative: a future where identifying a disease could, in theory, lead to the design for a corresponding drug with the simple click of a button, all powered by advanced AI tools.
Momentum Through Partnerships and Funding
Indicative of growing confidence in their AI-driven methodology, Isomorphic Labs has recently secured significant partnerships and funding. In 2024, the same year Google DeepMind released AlphaFold 3 with enhanced capabilities, Isomorphic Labs signed major research collaboration deals with two giants of the pharmaceutical industry: Novartis and Eli Lilly.
These collaborations demonstrate a willingness among established players to integrate advanced AI into their pipelines. A year later, in April 2025, Isomorphic Labs further solidified its position by raising $600 million in its first-ever external funding round, led by investment firm Thrive Capital. This substantial investment provides the resources necessary to scale operations and push towards clinical validation.
As part of its strategy, Isomorphic Labs works on drug programs alongside its pharma partners, but it is also cultivating its own pipeline of internal drug candidates. These proprietary programs are focused on areas of high unmet medical need, such as oncology (cancer) and immunology (disorders of the immune system). The plan is to advance these internal candidates through early-stage clinical trials with the aim of eventually licensing them out to larger pharmaceutical companies for later-stage development and commercialization.
The Broader Landscape of AI Adoption
While Isomorphic Labs pushes the boundaries of AI in drug discovery with bold ambitions, the broader landscape of AI adoption across industries presents a more complex picture, marked by both excitement and caution. Large tech companies like Alphabet are navigating significant strategic shifts, including managing talent amidst intense AI competition. Google, for instance, has recently implemented voluntary exit programs and stricter return-to-office policies, partly aimed at ensuring workforce alignment and commitment in this rapidly evolving environment, though such moves carry the risk of potentially losing high-performing employees.
The public reception to the “AI-first” concept has also seen pushback. Companies like Duolingo, which initially suggested prioritizing AI over human contractors, have tempered their rhetoric following criticism. Their CEO now emphasizes AI as a tool to enhance human work, not replace it, highlighting public skepticism regarding AI accuracy, potential data sourcing issues, and concerns about job security. Studies have even suggested that current AI applications haven’t yet delivered the significant productivity gains in white-collar work that some predicted, underscoring that the transition is nuanced and potentially slower than the technology’s potential might suggest in isolation.
Crucially, alongside the immense potential of AI, there is a growing acknowledgment of significant risks. Leaders in the field, such as Anthropic CEO Dario Amodei, have issued stark warnings about the potential for AI to displace large numbers of entry-level white-collar jobs in the near future, raising concerns about potential spikes in unemployment.
Adding another layer of complexity, Google DeepMind itself has openly discussed the potential downsides of highly advanced AI, particularly Artificial General Intelligence (AGI). A research paper from DeepMind has suggested AGI could plausibly arrive by 2030 but also warns of the potential for “severe harm,” including “existential risks” that could “permanently destroy humanity.” While DeepMind is actively researching safety protocols, they highlight various risk categories including misuse (intentional harm), misalignment (AI acting unpredictably), mistakes (system flaws), and structural risks (conflicts between entities using AI).
This self-awareness within DeepMind about the potential for negative outcomes from powerful AI provides a necessary counterpoint to the highly optimistic vision of curing diseases. It underscores that the same technology holding promise for revolutionary medical breakthroughs also presents profound societal and existential questions that require careful consideration and mitigation efforts.
Navigating the Future of AI Medicine
Isomorphic Labs’ imminent move to human clinical trials represents a critical juncture for AI in medicine. It moves the technology beyond computational models and into the complex reality of human biology and health outcomes. The potential rewards—faster, cheaper, more effective drug development—are immense, promising new treatments for devastating diseases.
However, the journey will also test the limits of AI’s current capabilities and raise important questions about validation, safety, and ethical deployment. As AI systems become more integrated into designing interventions that affect human health, the need for robust testing, transparency, and regulatory frameworks becomes paramount.
The path forward requires balancing groundbreaking innovation with rigorous scientific validation and a deep understanding of the broader implications of deploying powerful AI. Isomorphic Labs is not just developing drugs; it is pioneering a new paradigm for medical science, one powered by artificial intelligence, that could redefine the future of human health, provided the inherent risks of such powerful technology are carefully navigated.
Frequently Asked Questions
How does Google DeepMind’s AI find new drugs?
Google DeepMind’s spin-off, Isomorphic Labs, primarily uses advanced AI derived from AlphaFold technology. This AI can predict detailed protein structures and model how proteins interact with other molecules, including potential drug compounds. This capability allows researchers to identify disease targets and design new molecules more efficiently than traditional methods.
What kinds of diseases is Isomorphic Labs developing AI drugs for?
While collaborating with pharmaceutical partners on existing drug programs, Isomorphic Labs is also developing its own internal pipeline of drug candidates. These internal programs are focused on areas of high medical need, specifically mentioning oncology (cancer) and immunology (diseases affecting the immune system).
When will Google’s AI-designed drugs be tested in humans?
According to Isomorphic Labs’ president, Colin Murdoch, human clinical trials are the company’s “next big milestone” and are “in sight.” The company is currently staffing up and making preparations, indicating they are getting “very close” to initiating the first human trials for their AI-designed drug candidates.
